Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Poolbeg Pharma and CytoReason identify "very exciting influenza targets" By: News Direct June 29, 2023 at 03:54 AM EDT --News Direct--Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington and CytoReason co-founder and CEO David Harel speak to Thomas Warner from Proactive after announcing what they call a "significant breakthrough" in their world-first influenza Artificial Intelligence ('AI') Programme. Skillington says that the collaboration has yielded some "very exciting influenza targets" and that Poolbeg will now be "actively exploring the most effective way to bring them forward into development." He also highlights Poolbeg's RSV-focused AI collaboration with CytoReason that concluded in 2022, saying that Poolbeg "is now working on validating those targets... and will have data before the end of the year."Contact DetailsProactive UK Ltd+44 20 7989 0813uk@proactiveinvestors.comView source version on newsdirect.com: https://newsdirect.com/news/poolbeg-pharma-and-cytoreason-identify-very-exciting-influenza-targets-850721061 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Poolbeg Pharma and CytoReason identify "very exciting influenza targets" By: News Direct June 29, 2023 at 03:54 AM EDT --News Direct--Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington and CytoReason co-founder and CEO David Harel speak to Thomas Warner from Proactive after announcing what they call a "significant breakthrough" in their world-first influenza Artificial Intelligence ('AI') Programme. Skillington says that the collaboration has yielded some "very exciting influenza targets" and that Poolbeg will now be "actively exploring the most effective way to bring them forward into development." He also highlights Poolbeg's RSV-focused AI collaboration with CytoReason that concluded in 2022, saying that Poolbeg "is now working on validating those targets... and will have data before the end of the year."Contact DetailsProactive UK Ltd+44 20 7989 0813uk@proactiveinvestors.comView source version on newsdirect.com: https://newsdirect.com/news/poolbeg-pharma-and-cytoreason-identify-very-exciting-influenza-targets-850721061
--News Direct--Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington and CytoReason co-founder and CEO David Harel speak to Thomas Warner from Proactive after announcing what they call a "significant breakthrough" in their world-first influenza Artificial Intelligence ('AI') Programme. Skillington says that the collaboration has yielded some "very exciting influenza targets" and that Poolbeg will now be "actively exploring the most effective way to bring them forward into development." He also highlights Poolbeg's RSV-focused AI collaboration with CytoReason that concluded in 2022, saying that Poolbeg "is now working on validating those targets... and will have data before the end of the year."Contact DetailsProactive UK Ltd+44 20 7989 0813uk@proactiveinvestors.comView source version on newsdirect.com: https://newsdirect.com/news/poolbeg-pharma-and-cytoreason-identify-very-exciting-influenza-targets-850721061